[Does hormonal contraception increase the risk for tumors?]
review
OA: closed
public-domain-us
AI-generated summary
Oral hormonal contraceptives are associated with a diminished risk for benign breast tumors, uterine fibroids, ovarian cysts, endometrial cancer, and colorectal cancer, while not increasing the risk for breast, liver, melanoma, vulvar, or vaginal cancers.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
A non-contraceptive benefit of oral hormonal contraceptives (OC) is a diminished risk for certain benign as well as malignant tumours, such as benign breast tumours, uterine fibroids and ovarian cysts. Endometriosis itself is not positively influenced by OC, but dysmenorrhea is decreased. Modern low-dose OC do not increase the risk of liver cell adenomata or carcinomata. OC do not influence melanoma. Modern data do not suggest an increased risk for breast carcinoma in OC users. Long-term use of OC leads to a decreased risk of endometrial and colorectal carcinomata. Cervical carcinoma is not influenced directly by OC, but probably indirectly through a change in sexual behaviour. There is no increase of vulvar or vaginal carcinoma, even after long-term use of OC.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-10-01T06:15:55.914501+00:00
- pubmed
- last seen: 2026-05-13T22:14:18.065553+00:00
- unpaywall
- last seen: 2026-05-14T19:30:52.867331+00:00
License: public-domain-us
· commercial use OK
· attribution required
Courtesy of the U.S. National Library of Medicine
Courtesy of the U.S. National Library of Medicine